Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Fineline Cube Dec 29, 2025
Company Medical Device

Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation

Fineline Cube Jul 25, 2025

China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...

Company Deals

3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707

Fineline Cube Jul 25, 2025

China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...

Company

Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion

Fineline Cube Jul 25, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting...

Company Drug

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer

Fineline Cube Jul 25, 2025

China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375/VS-7375,...

Company Deals

Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO

Fineline Cube Jul 25, 2025

China-based Leads Biolabs (HKG: 9887) officially listed on the Main Board of the Hong Kong...

Company Deals

Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization

Fineline Cube Jul 25, 2025

China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...

Company Drug

Yangtze River Pharmaceutical’s Tadalafil Hydrochloride Tablets Approved for ED Treatment in China

Fineline Cube Jul 25, 2025

China-based Yangtze River Pharmaceutical Group announced on July 25, 2025, that its Class 1 innovative...

Company Drug

Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors

Fineline Cube Jul 25, 2025

France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx...

Policy / Regulatory

NHSA Announces Reforms to Centralized Drug Procurement Policies Beyond Lowest Price

Fineline Cube Jul 24, 2025

The National Healthcare Security Administration (NHSA) held a press conference today on the “High-Quality Completion...

Company

Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025

Fineline Cube Jul 24, 2025

Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...

Company Drug

Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment

Fineline Cube Jul 24, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on July 23, 2025, that its partner...

Company Drug

Sirius Therapeutics’ SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases

Fineline Cube Jul 24, 2025

China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has...

Company Drug

Akeso Enrolls First Patient in Phase III Trial of Ivonescimab for Pancreatic Cancer

Fineline Cube Jul 24, 2025

China-based Akeso Biopharma (HKG: 9926) announced on July 24, 2025, that the first patient has...

Company Drug

Youcare Pharma’s YKYY029 Receives FDA IND Approval for Hypertension Treatment

Fineline Cube Jul 24, 2025

China-based Youcare Pharmaceutical Group (SHA: 688658) announced on July 24, 2025, that its subsidiary, Beijing...

Policy / Regulatory

National Health Commission Launches Integrated Medical and Elder Care Demonstration Projects

Fineline Cube Jul 24, 2025

On July 22, 2025, China’s National Health Commission (NHC) issued the “Work Plan for Integrated...

Company Drug

Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial

Fineline Cube Jul 24, 2025

China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826...

Company Deals

Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax

Fineline Cube Jul 23, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation...

Company Medical Device

Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA

Fineline Cube Jul 23, 2025

China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that...

Company Drug

Shenzhen Beimei’s TWYNEO Receives NMPA Clinical Trial Approval for Acne Treatment

Fineline Cube Jul 23, 2025

Shenzhen Beimei Pharmaceutical Co., Ltd. announced on July 22, 2025, that its drug TWYNEO (tretinoin...

Company Deals

Chison Medical and Gates Foundation Collaborate on Innovative Ultrasound Equipment

Fineline Cube Jul 23, 2025

China-based Chison Medical Technologies (SHA: 688358) announced on July 23, 2025, a partnership with the...

Posts pagination

1 … 59 60 61 … 602

Recent updates

  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
  • Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.